諾誠健華:二零二三年年報
Zhitong Hong Kong Shareholders' Rights Disclosure | April 15
According to data from the Zhitong Finance App, China Jinmao (00817), Nuocheng Jianhua (09969), Sunshine 100 China (02608), BOE Precision (00710), and Anle Engineering (01977) made the latest shareholders' rights disclosure on April 15, 2024. Stock name Institutional name Change of nature of shares before change of shareholding ratio China Jinmao (00817) Zhang Hui had a good position of 4.4840 million shares 8.484 million shares 0.06% (latest) 0.03% (previous), Nuocheng Jianhua (09969) King Bridge Inves
InnoCare Pharma Limited (HKG:9969) Surges 5.2%; Retail Investors Who Own 32% Shares Profited Along With Insiders
Key Insights Significant control over InnoCare Pharma by retail investors implies that the general public has more power to influence management and governance-related decisions The top 9 shareholde
Looking for new pharmaceutical productivity: Looking at the high-quality development of local innovative pharmaceutical companies from Nuochengjianhua (9969.HK/688428.SH)
“New quality productivity” is becoming one of the most popular terms recently. In March 2024, the report on the work of the Chinese government identified “developing new quality productivity” as the top priority at present. Among them, innovative drugs are clearly mentioned for the first time in the “Actively Cultivating Emerging Industries and Future Industries” section, stating that it is necessary to “accelerate the development of the cutting-edge and emerging innovative drug industry, actively build a new growth engine for biomantry manufacturing, open up a new life science circuit, and create a number of pioneering zones for future industries” to add another spring breeze to the innovative drug circuit. Well, in an age where the innovative drug industry is receiving so much attention from top-level design, it
Read Nuochengjianhua's 2023 performance report in one picture
On March 28, Nuochengjianhua announced its 2023 performance report. The following will take you to read Nuochengjianhua's 2023 performance report with a picture.
INNOCARE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Nuochengjianhua (688428.SH) announces 2023 annual results, core product sales growth, net loss narrows to 631 million yuan
Nuochengjianhua (688428.SH) disclosed its 2023 annual report. The company achieved operating income of 7 during the reporting period...
Nuocheng Jianhua (09969.HK) held a board meeting on March 28 to consider and approve the annual results
Glonghui March 15 | Nuochengjianhua (09969.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
INNOCARE: DATE OF BOARD MEETING
Changes in Hong Kong stocks | Nuochengjianhua (09969) has now risen more than 4%, and the BCL2 inhibitor ICP-248 combined with obutinib has been clinically approved for treatment of CLL/SLL
Nuocheng Jianhua (09969) is now up more than 4%. As of press release, it has risen 4.51% to HK$5.33, with a turnover of HK$396.03 million.
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination With Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
Nuochengjianhua (09969) oral report on the latest clinical data on TYK2 inhibitors
Nuochengjianhua (09969) orally reported the latest clinical data on TYK2 inhibitors.
Nuocheng Jianhua (09969) spent about HK$1,523,700 to buy back 300,000 shares on February 23
Nuocheng Jianhua (09969) announced that on February 23, 2024, it cost approximately HK$1,523,700 to repurchase 300,000...
Nuocheng Jianhua (09969) spent HK$400,000 to buy back 84,000 shares on February 15
According to the Zhitong Finance App, Nuocheng Jianhua (09969) issued an announcement to spend HK$400,000 to repurchase 84,000 shares on February 15, 2024, at a repurchase price of HK$4.54-4.85 per share.
Does InnoCare Pharma (HKG:9969) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Nuochengjianhua (09969.HK) spent HK$900,000 to buy back 88,000 shares on February 14
Glonghui, Feb. 14 | Nuochengjianhua (09969.HK) announced that on February 14, it spent HK$900,000 to repurchase 188,000 shares at a price of HK$4.75-4.81 per share.
Nuocheng Jianhua (09969) spent about HK$901,000 to buy back 88,000 shares on February 14
Nuocheng Jianhua (09969) announced that on February 14, 2024, it cost about HK$901,000 to repurchase 180,000...
Nuocheng Jianhua (09969) spent about HK$741,700 to buy back 150,000 shares on February 9
Nuocheng Jianhua (09969) announced that on February 9, 2024, it spent about HK$741,700 to repurchase 150,000 shares...
Selected Gelonghui Announcements (Hong Kong Stocks) | CITIC Securities (06030.HK): Huaxia Fund Achieves Net Profit of RMB 2,013 Million in 2023
[Today's Focus] CITIC Securities (06030.HK): Huaxia Fund achieved net profit of 2,013 billion yuan in 2023, CITIC Securities (06030.HK) issued an announcement. As of December 31, 2023, Huaxia Fund had total assets of RMB 18.794 billion and total liabilities of RMB 5.642 billion; in 2023, it achieved operating income of RMB 7.327 billion, net profit of RMB 2,013 billion, and total comprehensive income of RMB 2,028 billion. As of December 31, 2023, Huaxia Fund's parent company managed assets of RMB 18,235.6
Nuocheng Jianhua (09969.HK) spent HK$1.02 million to repurchase 200,000 shares on February 8
Glonghui, Feb. 8 | Nuocheng Jianhua (09969.HK) announced that on February 8, it spent HK$1.02 million to repurchase 200,000 shares at a price of HK$5.04-5.11 per share.
No Data